Avenzo Therapeutics
San Diego, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $660M
Overview
Developing next-generation small molecule cancer therapies to overcome treatment resistance.
Oncology
Technology Platform
Utilizes structure-based drug design and computational chemistry to develop selective small molecule kinase inhibitors for oncology.
Funding History
5Total raised:$660M
Series A$60M
Series D$150M
Series C$150M
Series B$150M
Opportunities
Significant market potential exists for effective therapies that can overcome resistance in later-line cancer patients.
Risk Factors
Clinical failure of its lead candidate, which is common in oncology drug development, poses an existential threat.
Competitive Landscape
Operates in the highly competitive kinase inhibitor space, requiring differentiation from numerous approved and developmental agents.